High Grade Cervical Intraepithelial Neoplasia
Conditions
Keywords
HSIL, CIN 2/3, Therapeutic DNA vaccine, Human Papillomavirus, Immunotherapy
Brief summary
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3). This study will recruit approximately 27-40 female patients with high grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) at multiple sites in Europe.
Detailed description
The study will be divided into two phases, a dosing and expansion phase. During the dosing phase the safety, tolerability and immunogenicity of 2 different vaccination schedules of 3 mg VB10.16 immunotherapy will be established in a minimum of 12 patients with histology confirmed CIN 2. During the expansion phase the safety, tolerability and immunogenicity of the selected vaccination schedule will be evaluated in approximately 15 to 20 patients with histology confirmed HPV16+ CIN 2/3.
Interventions
BIOLOGICALVB10.16 Immunotherapy (DNA vaccine)
Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
Sponsors
Theradex
Vaccibody AS
Nykode Therapeutics ASA
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(abbreviated): 1. Women ≥18 years 2. Women with ectocervical HPV16+ associated High Grade Cervical Intraepithelial Neoplasia (HSIL) as verified by local pathology: (Dosing Phase: Women with histologically confirmed HPV16+ associated CIN 2; Expansion Phase: Women with histologically confirmed HPV16+ associated CIN 2/3) 3. Satisfactory colposcopic examination.
Exclusion criteria
(abbreviated): 1. More than 2 cervical quadrants of CIN 3 as visualised by colposcopy. 2. Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease. 3. Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination. 4. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV). 5. Administration of any blood product within 3 months of enrolment. 6. Concomitant or prior malignant disease. 7. Clinically significant autoimmune disease. 8. Known allergy to Kanamycin or other aminoglycosides 9. Known immunodeficiency and or immunosuppression. 10. History of toxic shock syndrome. 11. Evidence or history of clinically significant cardiac disease 12. Active infection requiring parenteral antibiotics. 13. Tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination or any implantable leads. 14. Immunosuppression 15. Major surgery within 3 months of trial entry. 16. Current or recent (within 30 days of first study treatment) participation in a clinical trial. 17. Previous vaccination (either therapeutic and/or prophylactic) against HPV. 18. Administration of any live vaccine within 90 days of trial entry. 19. Concomitant anticancer therapies. 20. Inadequate bone marrow function 21. Inadequate liver function 22. Clinical significant electrolyte abnormalities 23. Women of childbearing age not willing to use an effective form of contraception 24. Pregnancy or intention to become pregnant 25. Nursing women 26. Evidence of any other medical condition that may interfere with study participation, patient compliance or place the patient at high risk from treatment-related complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety/tolerability | 6 months (extended follow up for additional 6 months) | \- The percentage of patients with adverse events (AEs), including any dose-limiting toxicities (DLT), laboratory assessments and physical findings. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity | 6 months | * The percentage of patients with E6/E7 specific cellular immune response in the blood. * The percentage of patients with cellular immune response in the target lesions. * The percentage of patients with humoral response against the E6/E7 viral antigen. |
| Preliminary assessment of efficacy | 6 months (extended follow up for additional 6 months) | * The percentage of patients with HPV16+ clearance. * The percentage of patients with lesion regression |
Countries
Germany
Outcome results
None listed